Deals10 Jun 2021 22:49
Feel free to correct me when I m wrong. SOH basic business proposition is to sign deals in different geographical areas and different patents related to OPTI slash Skin. The logic being that this diverse number of deals significantly reduces both the risk and cost. The costs are largely borne by the companies signing the deals. The problem with this strategy being OPTI has little or no control on how or even if the product is bought to the market. If the post regarding 72 deals for 1.5 million revenue is correct then the average revenue per deal is circa £27,000 which quite frankly is pathetic. One argument put forward is that it takes several years to put in place the logistics distribution marketing etc for each deal. Fair enough, but does the current structure encourage optis partners to prevaricate instead of pushing the product? I understand a massive deal with RNS would shoot the share price significantly higher, however where is this deal? Its hinted at, but has been since 2015 so each time the jam tomorrow is dangled it loses a little credibility. On the other hand this share seems to have a resistance around 48-49 pence which makes sense given the fact that revenues have in general grown year on year. Stockopedia rates this share as a speculative sucker, not too encouraging. The market in which optibiotix operates is growing but are opti in the mix or is there product becoming old technology? I dont know, anybody who wishes to enlighten me please go ahead. I suspect at heart the real reason a significant number of people hold this share is that if one just one of those 72 deals does what it says on the tin we are rich men. If holding Opti has taught anybody anything it must be Patience.